DDI2–NFE2L1 Pathway: A Key Regulator of Ferroptosis via the Ubiquitin-Proteasome System

Study Background and Research Question

Ferroptosis is a distinct, iron-dependent form of regulated cell death characterized by lipid peroxidation and loss of plasma membrane integrity. Unlike apoptosis, ferroptosis is intimately linked to metabolic and redox imbalances, and it has been implicated in the progression of neurodegeneration, cancer, and other pathologies. The cell's ability to mitigate oxidative stress—particularly through mechanisms such as glutathione peroxidase 4 (GPX4) activity—is well established, but the adaptive responses of protein homeostasis systems, especially the ubiquitin-proteasome system (UPS), to ferroptotic stress remain less understood.

The referenced study (Ofoghi et al., 2025) addresses the critical question: how does the interplay between the UPS and the transcription factor NFE2L1, through activation by the protease DDI2, influence cellular susceptibility to ferroptosis?

Key Innovation from the Reference Study

The central innovation lies in mapping a mechanistic link between ferroptosis initiation and adaptive adjustments in the UPS mediated by NFE2L1. The researchers demonstrate that ferroptotic stress induced by small molecules like RSL3 results in a feedback loop: proteasome inhibition leads to hyperubiquitylation and subsequent activation of the membrane-tethered transcription factor NFE2L1. Crucially, this activation depends on proteolytic cleavage by the aspartyl protease DDI2. When DDI2 is inhibited—either genetically or pharmacologically—cells cannot appropriately activate NFE2L1, resulting in persistent proteasome dysfunction and increased susceptibility to ferroptosis. This insight reveals a potential therapeutic target for sensitizing cells to ferroptosis, with translational relevance for cancer therapy strategies.

Methods and Experimental Design Insights

The study employed a combination of unbiased proteomics, genetic manipulation, and chemical induction approaches:

• Proteomic profiling: Global ubiquitylation site mapping was performed to assess proteome-wide impacts of ferroptosis induction using RSL3, a direct GPX4 inhibitor.
• Genetic approaches: Knockout models lacking DDI2 or NFE2L1 were generated to dissect pathway dependencies.
• Proteasome activity assays: Measurements of 26S proteasome function provided quantitative assessment of UPS recalibration under ferroptotic stress.
• Pharmacological inhibition: The clinical HIV-1 protease inhibitor nelfinavir was used as a DDI2 inhibitor to probe chemical modulation effects on this axis.
• Cell viability and death assays: Multiple assays confirmed that disruption of the DDI2–NFE2L1 pathway exacerbates ferroptotic cell death.

Protocol Parameters

• Ferroptosis induction: RSL3 employed at concentrations sufficient to inhibit GPX4 and trigger lipid peroxidation, with exposure times optimized for cell-type susceptibility.
• UPS activity monitoring: Use of ubiquitin linkage-specific antibodies and fluorogenic proteasome substrates for real-time activity tracking in treated cell lysates.
• DDI2 inhibition: Nelfinavir applied at concentrations consistent with previous DDI2-inhibition studies; time courses aligned with the onset of NFE2L1 activation following ferroptosis induction.
• Genetic knockout validation: Confirmation of DDI2 or NFE2L1 deficiency by immunoblotting and qRT-PCR for downstream proteasome subunit gene expression.

Core Findings and Why They Matter

Ofoghi et al. (2025) establish several pivotal findings:

• Ferroptosis triggers proteasome inhibition and protein hyperubiquitylation: Induction of ferroptosis with RSL3 leads to a decrease in proteasomal activity and accumulation of polyubiquitylated proteins, highlighting a feedback mechanism to restore proteostasis.
• NFE2L1 activation is essential for adaptive proteasome recovery: NFE2L1 upregulates proteasome subunit genes upon activation, providing a protective response to restore UPS function and mitigate ferroptotic stress.
• Proteolytic activation of NFE2L1 by DDI2 is necessary: DDI2-deficient cells are unable to mount the NFE2L1-mediated proteasome recovery, resulting in increased vulnerability to ferroptosis.
• Nelfinavir sensitizes cells to ferroptosis by inhibiting DDI2: Treatment with nelfinavir, a clinical HIV-1 protease inhibitor, phenocopies DDI2 loss and enhances ferroptotic cell death, underscoring the translational relevance of targeting this pathway.

Collectively, these results clarify how adaptive protein quality control mechanisms intersect with regulated cell death, and they propose the DDI2–NFE2L1 axis as a potential lever for therapeutic intervention, particularly in oncology where ferroptosis induction is of interest.

Comparison with Existing Internal Articles

Several internal resources contextualize the dual research utility of nelfinavir:

• Nelfinavir Mesylate: Applied HIV-1 Protease Inhibition &... highlights practical workflows for using nelfinavir in both HIV suppression and ferroptosis modulation, aligning with the reference study’s demonstration of nelfinavir as a DDI2 inhibitor.
• Nelfinavir Mesylate: Advanced HIV-1 Protease Inhibitor Wo... further discusses the compound’s impact on protein homeostasis and regulated cell death, reinforcing its value as a tool for studying the proteasome-ferroptosis axis.
• Nelfinavir Mesylate at the Vanguard: Mechanistic Innovati... bridges the link between antiviral research and cell death mechanisms, specifically referencing the emerging role of nelfinavir in modulating the DDI2–NFE2L1 axis and UPS function.

By integrating these workflows, researchers can design experiments that address both classical virology questions (e.g., HIV replication suppression) and advanced cell death modeling, leveraging the compound’s dual action as a HIV-1 protease inhibitor and a modulator of protein homeostasis.

Limitations and Transferability

While the study provides a robust mechanistic framework, several limitations are noteworthy:

• Model system constraints: Most findings are derived from cell lines and in vitro assays; the translation to in vivo or clinical contexts requires further validation.
• Specificity of DDI2 inhibition: Although nelfinavir is shown to inhibit DDI2 and sensitize cells to ferroptosis, its broad protease inhibition profile warrants caution when attributing effects exclusively to DDI2 blockade.
• Disease context: The therapeutic window and safety of manipulating the DDI2–NFE2L1 axis—especially in cancer versus non-cancerous tissues—remain to be fully determined.

Transferability is high for mechanistic studies in cellular models but must be carefully evaluated for translational or therapeutic applications.

Why this cross-domain matters, maturity, and limitations

This research exemplifies a cross-domain bridge between virology, cancer biology, and protein homeostasis. By leveraging a clinically approved antiretroviral drug for HIV treatment—nelfinavir—as a chemical probe for the DDI2–NFE2L1–UPS axis, the study opens new avenues for repurposing existing therapeutics in cell death modulation and cancer therapy. The maturity of this approach is supported by robust in vitro evidence, but further work is needed to assess long-term outcomes, selectivity, and in vivo feasibility. Limitations include the potential for off-target effects and the need for precise protocol optimization to distinguish DDI2-specific outcomes from broader protease inhibition phenomena.

Research Support Resources

Researchers aiming to reproduce or extend these findings can utilize Nelfinavir Mesylate (SKU A3653) as both a well-characterized HIV-1 protease inhibitor and a tool for probing DDI2 function in ferroptosis and protein homeostasis assays. According to the product information, nelfinavir demonstrates nanomolar efficacy, strong oral bioavailability, and a favorable safety profile in cell-based systems. For detailed workflows and troubleshooting guidance, the internal articles linked above provide actionable protocols spanning virology and cell death pathway research, supporting advanced assay development in both fields.